Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings.
暂无分享,去创建一个
D. Chan | P. Walsh | L. Sokoll | J. Epstein | J. L. Cox | R. Wolfert | H. Carter | J I Epstein | D W Chan | H B Carter | P C Walsh | L J Sokoll | H. Rittenhouse | J L Cox | H Rittenhouse | R Wolfert | Daniel W. Chan | Harry G. Rittenhouse | Robert L. Wolfert | D. Chan | H. Ballentine Carter | Jonathan I. Epstein | Patrick C. Walsh | H. Carter | Jonathan I. Epstein | Daniel W. Chan | Lori J. Sokoll | Patrick C. Walsh | Jennifer L. Cox | Jennifer L. Cox | J. I. Epstein
[1] E. Metter,et al. Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. , 1997, Urology.
[2] M W Kattan,et al. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. , 1996, The Journal of urology.
[3] P. Scardino,et al. Comparison of the pathologic features and DNA ploidy value of prostate cancers detectable by sonography and by palpation , 1993, The Prostate.
[4] P. Humphrey,et al. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. , 1996, The Journal of urology.
[5] P. Walsh,et al. Prospective evaluation of men with stage T1C adenocarcinoma of the prostate. , 1997, Journal of Urology.
[6] J. Oesterling,et al. Clinical Stage B0 or T1c prostate cancer: nonpalpable disease identified by elevated serum prostate-specific antigen concentration. , 1993, Urology.
[7] T. Stamey,et al. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate , 1990, Cancer.
[8] M. Koch,et al. Tumor volume and stage in carcinoma of the prostate detected by elevations in prostate specific antigen. , 1994, The Journal of urology.
[9] W. Fair,et al. Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy. , 1997, Urology.
[10] J. Moul,et al. Prostate‐specific antigen‐detected prostate cancer (Stage T1c): An analysis of whole‐mount prostatectomy specimens , 1997, The Prostate.
[11] E. Bergstralh,et al. Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. , 1996, The Journal of urology.
[12] P. Walsh,et al. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. , 1993, The Journal of urology.
[13] J. Fracchia,et al. PSA‐detected prostate cancer: Contrasts with palpable disease , 1995, Journal of surgical oncology.
[14] M M Elhilali,et al. Reassessment of nonplanimetric transrectal ultrasound prostate volume estimates. , 1996, Urology.
[15] L. Baert,et al. Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens--a different view. , 1997, The Journal of urology.
[16] P. Walsh,et al. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. , 1997, The Journal of urology.
[17] D. Bostwick,et al. PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. , 1993, The Urologic clinics of North America.
[18] P. Walsh,et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.
[19] J. Fracchia,et al. The accuracy of transrectal ultrasound prostate volume estimation: Clinical correlations , 1996, Journal of clinical ultrasound : JCU.
[20] J. Oesterling,et al. Biopsy-proved prostate cancer in 100 consecutive men with benign digital rectal examination and elevated serum prostate-specific antigen level. Prevalence and pathologic characteristics. , 1993, Urology.
[21] J. Oesterling,et al. Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. , 1997, The Urologic clinics of North America.
[22] C M Tempany,et al. Accuracy of In‐Vivo Assessment of Prostatic Volume by MRI and Transrectal Ultrasonography , 1992, Journal of computer assisted tomography.
[23] J. Pannek,et al. The use of percent free prostate specific antigen for staging clinically localized prostate cancer. , 1998, The Journal of urology.